Abstract
A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-α-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88% and 66%, respectively. Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.
| Original language | English |
|---|---|
| Pages (from-to) | 4463-4469 |
| Number of pages | 7 |
| Journal | Anticancer Research |
| Volume | 25 |
| Issue number | 6 C |
| Publication status | Published - Nov 2005 |
Fingerprint
Keywords
- Biotherapy
- Chemotherapy
- Neuroendocrine carcinomas
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Treatment of metastatic neuroendocrine carcinomas based on WHO classification. / Artale, Salvatore; Giannetta, Laura; Cerea, Giulio; Pedrazzoli, Paolo; Schiavetto, Ilaria; Napolitano, Marcello; Veronese, Silvio; Bramerio, Emanuela; Gambacorta, Marcello; Vanzulli, Angelo; Pisconti, Salvatore; Pugliese, Raffaele; Siena, Salvatore.
In: Anticancer Research, Vol. 25, No. 6 C, 11.2005, p. 4463-4469.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of metastatic neuroendocrine carcinomas based on WHO classification
AU - Artale, Salvatore
AU - Giannetta, Laura
AU - Cerea, Giulio
AU - Pedrazzoli, Paolo
AU - Schiavetto, Ilaria
AU - Napolitano, Marcello
AU - Veronese, Silvio
AU - Bramerio, Emanuela
AU - Gambacorta, Marcello
AU - Vanzulli, Angelo
AU - Pisconti, Salvatore
AU - Pugliese, Raffaele
AU - Siena, Salvatore
PY - 2005/11
Y1 - 2005/11
N2 - A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-α-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88% and 66%, respectively. Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.
AB - A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-α-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88% and 66%, respectively. Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.
KW - Biotherapy
KW - Chemotherapy
KW - Neuroendocrine carcinomas
UR - http://www.scopus.com/inward/record.url?scp=28444436906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28444436906&partnerID=8YFLogxK
M3 - Article
C2 - 16334127
AN - SCOPUS:28444436906
VL - 25
SP - 4463
EP - 4469
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 6 C
ER -